Edition:
United States

Revance Therapeutics Inc (RVNC.O)

RVNC.O on Consolidated Issue listed on NASDAQ Global Market

30.75USD
22 Jun 2018
Change (% chg)

$0.20 (+0.65%)
Prev Close
$30.55
Open
$30.60
Day's High
$30.80
Day's Low
$29.70
Volume
1,417,666
Avg. Vol
336,277
52-wk High
$37.45
52-wk Low
$22.05

Chart for

About

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $842.90
Shares Outstanding(Mil.): 30.82
Dividend: --
Yield (%): --

Financials

  RVNC.O Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -3.43 -- --
ROI: -50.65 2.00 14.38
ROE: -52.67 3.49 16.08

BRIEF-Revance Reports Qtrly Loss Per Share $0.97

* REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018 Source text for Eikon: Further company coverage:

May 08 2018

Mylan teams up with Revance on biosimilar for Botox

NEW YORK Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

Feb 28 2018

CORRECTED-Mylan teams up with Revance on biosimilar for Botox

NEW YORK, Feb 28 Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

Feb 28 2018

BRIEF-Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14

* REVANCE THERAPEUTICS INC - ‍REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018​

Feb 28 2018

BRIEF-Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍

* REVANCE THERAPEUTICS SAYS ‍CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING​

Feb 28 2018

BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis

* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS

Jan 08 2018

BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018

* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018

Jan 04 2018

Earnings vs. Estimates